CpG‐loaded NPs induce TLR9‐mediated ACD and elicit immunogenicity in TLR9‐positive tumors. They effectively reprogram the tumor's immunosuppressive microenvironment and suppress tumor growth and recurrence. The gene discussed is TLR9; the disease is neoplasm.